LUMO Labs Backs Autoscriber to Advance Healthcare AI Voice Recognition

LUMO Labs is backing Dutch health-tech startup Autoscriber, which specializes in artificial intelligence (AI)-supported voice recognition software that can interpret healthcare consultation between doctors and patients, according to a Tuesday (Sept. 7) press release.

“The problem Autoscriber is solving is universal: reducing time and money spent on repetitive, administrative tasks by physicians while increasing transparency, comprehensibility and human interaction in deeply personal treatment situations,” LUMO Labs Founding Partner Andy Lürling said in the release.

He added that Autoscriber’s solution “is dynamic and highly scalable.”

See also: Digital Transformation in Healthcare Payments

The funding for Autoscriber is being provided by LUMO Labs investment arm LUMO Fund II TTT AI. The company is backing Autoscriber because the concept can “dramatically improve the lives of caregivers and patients,” according to the release.

Read also: 76% of Patients Want Digital Healthcare

The subscription-based Software-as-a-Service (SaaS) offering by Autoscriber is intended to help health professionals at hospitals and practices of all sizes, as well as general practitioners. Autoscriber “records, transcribes and extracts clinical concepts during consultations” and enables automatic integration into patients’ electronic health records, the release stated.

Autoscriber Co-Founder and CEO Jacqueline Kazmaier said in the release that LUMO Labs is the “perfect partner” as it works toward Autoscriber’s company mission of “enabling the future of healthcare.”

See more: Healthcare Providers Turn to AI to Rein in Fraudsters’ 240-Hour Head Start

The pre-seed funding from LUMO Labs will enable Autoscriber to go live in hospitals in less than a year, according to the release. The funding amount was not disclosed.

The technology was created in partnership with the Clinical Artificial Intelligence and Research Lab (CAIRELab) at Leiden University Medical Center.